Back to Education Zone

touchPANEL DISCUSSION

CAR-T in clinical practice: Navigating the patient
journey from referral to long-term follow-up

Introduction

Watch a panel of internationally renowned experts discuss the use of chimeric antigen receptor T-cell (CAR-T) therapy for diffuse large B-cell lymphoma (DLBCL).

Prof. Mohamad Mohty chairs a discussion with Dr John Kuruvilla and Dr Robin Sanderson on real-world data for CAR-T therapy in DLBCL and its possible impact on clinical practice, which patients should be assessed for their eligibility for CAR-T therapy and how referral and treatment centres can collaborate throughout a patient’s care.

This activity is intended for haematologists, oncologists, specialist nurses and other healthcare professionals involved in the care of patients with DLBCL.

This touchPANEL DISCUSSION was recorded in July 2020.

Learning Objectives

After watching this touchPANEL DISCUSSION, you should be able to:

  • Recall the latest real-world evidence for the use of chimeric antigen receptor T-cell (CAR-T) therapy in patients with diffuse large B-cell lymphoma (DLBCL)
  • Describe which patients with DLBCL should be referred for assessment for CAR-T therapy and discuss the importance of early referral
  • Discuss the roles of referral centres and treatment centres in patient management, in particular long-term follow up of patients

Clinical spotlight

  • What are we learning about chimeric antigen receptor T-cell (CAR-T) therapy in diffuse large B-cell lymphoma (DLBCL) from real-world data and how could it influence clinical practice?
  • Why is it important to refer patients early for CAR-T therapy assessment and how do we identify which patients should be referred?
  • What are the best ways for referral centres and treatment centres to collaborate to optimize patient care?

Clinical Spotlight

  • What are we learning about chimeric antigen receptor T-cell (CAR-T) therapy in diffuse large B-cell lymphoma (DLBCL) from real-world data and how could it influence clinical practice?
  • Why is it important to refer patients early for CAR-T therapy assessment and how do we identify which patients should be referred?
  • What are the best ways for referral centres and treatment centres to collaborate to optimize patient care?

The expert panel

PROF. MOHAMAD MOHTY

DR JOHN
KURUVILLA

DR ROBIN SANDERSON

PROF. MOHAMAD MOHTY

Mohamad Mohty is full Professor of Haematology and Head of the Haematology and Cellular Therapy Department at the Saint-Antoine Hospital and Sorbonne University in Paris, France.

Prof. Mohty obtained his medical degree from the University of Montpellier, France, and his PhD from the University of Marseille, France. He also undertook post-doctoral work at the Haematology Department, Imperial College, Hammersmith Hospital, London, UK. Prof. Mohty is head of a translational research team (INSERM team N°7) at the Saint-Antoine Research Centre in Paris and his research is focused on the pathophysiology and immunobiology of normal and pathological antigen-presenting cells. He has a special clinical focus on the development of reduced-toxicity conditioning regimens, immunotherapy and different aspects of therapy for acute leukaemia and multiple myeloma.

Prof. Mohty is past-president of the European Society for Blood and Marrow Transplantation (EBMT), and the current chairman of the Acute Leukaemia Working Party of EBMT. He is also the founder and chairman of the International Academy for Clinical Hematology (IACH). He serves on the board of the EBMT, and the Intergroupe Francophone du Myelome (IFM). He is a member of the American Society of Hematology (ASH), American Society for Clinical Oncology (ASCO), American Society for Blood and Marrow Transplantation, European Hematology Association (EHA), and EBMT.

Prof. Mohty has published more than 600 peer-reviewed articles in the field of stem cell transplantation, leukaemia and myeloma in different haematology and immunology journals. He also serves on the editorial board of multiple journals.

Disclosures: Personal fees from Amgen, BMS, Celgene, Novartis, Roche and Takeda. Grants and personal fees from Janssen, Jazz and Sanofi.

DR JOHN KURUVILLA

John Kuruvilla is Associate Professor of Medicine at the University of Toronto and a clinical investigator in the Division of Medical Oncology and Hematology at the Princess Margaret Cancer Centre in Toronto, Canada. He is a haematologist and member of the Lymphoma and the Autologous Blood and Marrow Transplant programmes at the Princess Margaret Cancer Centre.

Dr Kuruvilla’s research interests are the development of novel therapeutics in lymphoid malignancies and incorporating translational research into clinical trials. He is the lymphoma co-chair for the Canadian Cancer Trials Group (CCTG) as well as the chair of the Scientific Advisory Board of Lymphoma Canada.

Disclosures: Research support from AstraZeneca, Canadian Cancer Society, Janssen, Leukemia and Lymphoma Society Canada, Princess Margaret Cancer Foundation and Roche. Consultant for Abbvie, BMS, Gilead, Karyopharm, Merck, Roche and Seattle Genetics. Honoraria from Amgen, Antengene, AstraZeneca, Celgene, Gilead, Janssen, Karyopharm, Merck, Novartis, Pfizer, Roche, Seattle Genetics and TG Therapeutics. Scientific Advisory Board for Lymphoma Canada (chair).

DR ROBIN SANDERSON

Dr Robin Sanderson has a specialist interest in CAR T-cells, lymphoid disorders and stem cell transplantation. He completed his medical and haematological training at King’s College, St Bartholomew’s and Guy’s and St Thomas’ Hospitals in central London, UK, and haematology/transplant fellowships at Sydney teaching hospitals in Australia. He gained his certificate of completion of specialist training in haematology in 2014 followed by a PhD at the Barts Cancer Institute in London, UK. This was focused on investigating CAR T-cells in chronic lymphocytic leukaemia and lymphoma, and their modulation with immunotherapy in preclinical models. He was appointed Consultant Haemato-oncologist at King’s College Hospital to lead the lymphoma CAR T-cell programme in 2019.

Disclosures: Honoraria from Kite and Novartis.

Please feedback on this touchPANEL DISCUSSION on the following:
(scale 1-5, 1 strongly disagree; 5 strongly agree).